Core Viewpoint - Microbix Biosystems Inc. has entered into a multi-year agreement with the National Center for Infectious and Parasitic Diseases of Bulgaria (NCIPD) to develop new quality assessment products (QAPs™) using pathogen seedstocks supplied exclusively by NCIPD, aiming to enhance the accuracy of diagnostic tests for infectious diseases [1][2]. Company Overview - Microbix Biosystems Inc. is a life sciences innovator with nearly 40 years of experience in producing biological ingredients, particularly QAPs, which are critical for validating diagnostic tests [4][6]. - The company employs over 120 skilled workers and targets sales of C$ 2.0 million or more per month, exporting products to over 30 countries [6][8]. Partnership Details - The agreement with NCIPD includes a license fee, material-transfer fees, and royalties on net sales of related QAPs, allowing Microbix to commercialize multiple new QAPs that will support the accuracy of tests for diagnosing infectious diseases [2][5]. - NCIPD, established in 1881, is recognized as a leading institution in the field of infectious and parasitic diseases and has developed an extensive collection of characterized microorganisms [3][5]. Product Development - Microbix currently offers approximately 300 QAPs and expects to significantly increase this number through the collaboration with NCIPD, which will provide inactivated and stabilized mimetics of patient samples for test validation [4][2]. - The collaboration aims to ensure the accuracy of emerging tests for bacterial, parasitic, and viral infections, thereby improving global health outcomes [2][5].
Microbix & Bulgaria’s NCIPD Execute Supply Agreement